Illumina Appoints Nilesh Shah as New AMEA Regional Head Amid Leadership Shake-up

Recently, Illumina, Inc., the global leader in DNA sequencing and array-based technologies, announced the appointmentNilesh Shah is the head of the Asia-Pacific, Middle East, and Africa (AMEA) region., effective immediately.

Shah will be based in Singapore, taking over from Bas Verhoef, the interim head of the AMEA region.Bas VerhoefWill continue to serve as the head of the European region.

Nilesh has more than25 Years of Leadership Experience, once inJohnson & Johnson, GE HealthcareHold senior positions, most recently inWest Pharmaceutical ServicesServed as Vice President and General Manager of Emerging Markets. At Western Airlines, he successfully drove regional transformation, enhanced customer engagement, and achieved strong growth through agile and consistent strategies in the Asia-Pacific and Latin American regions.

"We are delighted to welcome Nilesh to Illumina. His deep expertise in healthcare and global markets will be a tremendous asset as we continue to expand the use of genomic technology in one of the most dynamic regions in the world."

About his new role, Nilesh said: "Genomics and multi-omics are transforming precision medicine and healthcare worldwide. I am honored to join Illumina as the head of AMEA and look forward to collaborating with our customers, partners, and ecosystem to unlock the full potential of these technologies.

"IAMEA is one of the most dynamic and fastest-growing regions in the world, with tremendous opportunities to expand access to genomic technologies. We look forward to seeing how Nilesh's leadership will help shape a new chapter of growth and impact across the region," said Everett Cunningham, Chief Commercial Officer of Illumina.

"Genomics and multi-omics are rapidly transforming precision medicine and reshaping healthcare across all stages of life," said Nilesh. "I am honored to join Illumina as the head of AMEA. Together with our customers, partners, and the entire ecosystem, we will fully leverage the potential of these technologies — not only to promote regional health outcomes but also to improve the health of communities worldwide."

▲Source of the article: Overseas IVD Observer

▲Please indicate the above source for reprinting.

Disclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please exercise caution. If it involves issues related to the content, copyright, or other aspects of the work, to protect the rights and interests of both parties, please contact us and we will handle it immediately. If this article is reprinted by other platforms, they must take responsibility for the content themselves. The Medical Device Innovation Network is not responsible for any secondary dissemination caused by reprints.

Previous Recommendations

BD, 125.4 Billion Yuan Sale!

Fined $3.2 Billion, Johnson & Johnson Refuses to Comply

$7.2 Billion! Giant Goes Private in Delisting

Medical Device Companies in the IPO Race: Who Will Take the Baton from NorthX Life?